IP Strategies for Health Sciences Startups

IP Strategies for Health Sciences Startups

Speaking Engagement
Biotech and medical device companies are heavily dependent on intellectual property rights, particularly those developing diagnostic, therapeutic or invasive products. The complexity of the technology and rapidly evolving legal landscape make the availability, validity and enforceability of biotech patents highly uncertain. This session, led by Michael Twomey, a patent attorney and partner at WilmerHale, will explore some of the basic IP questions facing health sciences startups.

Read More About the Event

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.